Advertisement

Social Psychiatry and Psychiatric Epidemiology

, Volume 50, Issue 8, pp 1267–1276 | Cite as

Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study

  • Ragnar Nesvåg
  • Gun Peggy Knudsen
  • Inger Johanne Bakken
  • Anne Høye
  • Eivind Ystrom
  • Pål Surén
  • Anne Reneflot
  • Camilla Stoltenberg
  • Ted Reichborn-Kjennerud
Original Paper

Abstract

Purpose

To compare the prevalence and pattern of comorbid substance use disorders (SUD) between patients with schizophrenia, bipolar disorder, and depressive illness.

Methods

Data on presence of alcohol use disorder (AUD) and non-alcohol drug use disorder (DUD) were retrieved from the Norwegian Patient Register for individuals born between 1950 and 1989 who in the period 2009–2013 were diagnosed with schizophrenia, bipolar disorder or depressive illness according to the 10th version of the WHO International Classification of Diseases. The prevalence of AUD only, DUD only, or both was compared between men and women across age and diagnostic groups.

Results

The prevalence of SUD was 25.1 % in schizophrenia (AUD: 4.6 %, DUD: 15.6 %, AUD and DUD: 4.9 %), 20.1 % in bipolar disorder (AUD: 8.1 %, DUD: 7.6 %, AUD and DUD: 4.4 %), and 10.9 % in depressive illness (AUD: 4.4 %, DUD: 4.3 %, AUD and DUD: 2.2 %). Middle-aged men with bipolar disorder had the highest prevalence of AUD (19.1 %) and young men with schizophrenia had the highest prevalence of DUD (29.6 %). Of the specific DUDs, all but sedative use disorder were more prevalent in schizophrenia than the other groups. Cannabis and stimulant use disorder was found among 8.8 and 8.9 %, respectively, of the men with schizophrenia.

Conclusions

The alarmingly high prevalence of DUD among young patients with severe mental disorders should encourage preventive efforts to reduce illicit drug use in the adolescent population.

Keywords

Schizophrenia Bipolar disorder Depression Substance-related disorders Registry 

Notes

Acknowledgments

This project was funded by the Norwegian Institute of Public Health. We thank Martin Mydske Nilsen for practical support.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Negrete JC (2003) Clinical aspects of substance abuse in persons with schizophrenia. Can J Psychiatry 48:14–21PubMedGoogle Scholar
  2. 2.
    Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K (2004) Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res 67:157–166PubMedCrossRefGoogle Scholar
  3. 3.
    Turkington A, Mulholland CC, Rushe TM, Anderson R, McCaul R, Barrett SL, Barr RS, Cooper SJ (2009) Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. Br J Psychiatry 195:242–248PubMedCrossRefGoogle Scholar
  4. 4.
    Cantor-Graae E, Nordström LG, Mcneil TF (2001) Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 48:69–82PubMedCrossRefGoogle Scholar
  5. 5.
    Opsal A, Clausen T, Kristensen O, Elvik I, Joa I, Larsen TK (2011) Involuntary hospitalization of first-episode psychosis with substance abuse during a 2-year follow-up. Acta Psychiatr Scand 124:198–204PubMedCrossRefGoogle Scholar
  6. 6.
    Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D (2002) Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 62:743–755PubMedCrossRefGoogle Scholar
  7. 7.
    Lagerberg TV, Andreassen OA, Ringen PA, Berg AO, Larsson S, Agartz I, Sundet K, Melle I (2010) Excessive substance use in bipolar disorder is associated with impaired functioning rather than clinical characteristics, a descriptive study. BMC Psychiatry 10:9. doi: 10.1186/1471-244X-10-9 PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiological Catchment Area (ECA) Study. JAMA 264:2511–2518PubMedCrossRefGoogle Scholar
  9. 9.
    Kendler KS, Gallagher TJ, Abelson JM, Kessler RC (1996) Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry 53:1022–1031PubMedCrossRefGoogle Scholar
  10. 10.
    Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, Ruan WJ, Huang B (2005) Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiatry 66:1205–1215PubMedCrossRefGoogle Scholar
  11. 11.
    Hasin DS, Goodwin RD, Stinson FS, Grant BF (2005) Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on alcoholism and related conditions. Arch Gen Psychiatry 62:1097–1106PubMedCrossRefGoogle Scholar
  12. 12.
    Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan TH (2006) Substance abuse in first-episode non-affective psychosis. Schizophr Res 88:55–62PubMedCrossRefGoogle Scholar
  13. 13.
    Nesvåg R, Lange EH, Faerden A, Barrett EA, Emilsson B, Ringen PA, Andreassen OA, Melle I, Agartz I (2010) The use of screening instruments for detecting alcohol and other drug use disorders in first-episode psychosis. Psychiatry Res 177:228–234PubMedCrossRefGoogle Scholar
  14. 14.
    Ringen PA, Melle I, Birkenaes AB, Engh JA, Faerden A, Jónsdóttir H, Nesvåg R, Vaskinn A, Friis S, Larsen F, Opjordsmoen S, Sundet K, Andreassen OA (2008) Illicit drug use in patients with psychotic disorders compared with that in the general population: a cross-sectional study. Acta Psychiatr Scand 117:133–138PubMedCrossRefGoogle Scholar
  15. 15.
    Neale MC, Kendler KS (1995) Models of comorbidity for multifactorial disorders. Am J Hum Genet 57:935–953PubMedCentralPubMedGoogle Scholar
  16. 16.
    Kessler RC, Birnbaum H, Demler O, Falloon IR, Gagnon E, Guyer M, Howes MJ, Kendler KS, Shi L, Walters E, Wu EQ (2005) The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry 58:668–676PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J (2009) Prevalence of alcohol use disorders in schizophrenia—a systematic review and meta-analysis. Acta Psychiatr Scand 120:85–96PubMedCrossRefGoogle Scholar
  18. 18.
    Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J (2010) Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36:1115–1130PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64:543–552PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z (2011) Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry 68:241–251PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Cerullo MA, Strakowski SM (2007) The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy 2:29. doi: 10.1186/1747-597X-2-29 PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Kringlen E, Torgersen S, Cramer V (2001) A Norwegian psychiatric epidemiological study. Am J Psychiatry 158:1091–1098PubMedCrossRefGoogle Scholar
  23. 23.
    Kringlen E, Torgersen S, Cramer V (2006) Mental illness in a rural area: a Norwegian psychiatric epidemiological study. Soc Psychiatry Psychiatr Epidemiol 41:713–719PubMedCrossRefGoogle Scholar
  24. 24.
    Ringen PA, Lagerberg TV, Birkenaes AB, Engn J, Faerden A, Jónsdottir H, Nesvåg R, Friis S, Opjordsmoen S, Larsen F, Melle I, Andreassen OA (2008) Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder. Psychol Med 38:1241–1249PubMedCrossRefGoogle Scholar
  25. 25.
    Di Forti M, Morrison PD, Butt A, Murray RM (2007) Cannabis use and psychiatric and cognitive disorders: the chicken or the egg? Curr Opin Psychiatry 20:228–234PubMedGoogle Scholar
  26. 26.
    Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Reis Marques T, Pariante C, Dazzan P, Mondelli V, Paparelli A, Kolliakou A, Prata D, Gaughran F, David AS, Morgan C, Stahl D, Khondoker M, Maccabe JH, Murray RM (2014) Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 40:1509–1517. doi: 10.1093/schbul/sbt181 PubMedCrossRefGoogle Scholar
  27. 27.
    Arseneault L, Cannon M, Witton J, Murray RM (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110–117PubMedCrossRefGoogle Scholar
  28. 28.
    Chambers RA, Krystal JH, Self DW (2001) A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 50:71–83PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8–19PubMedCrossRefGoogle Scholar
  30. 30.
    Berkson J (1946) Limitations of the application of fourfold table analysis to hospital data. Biom Bull 2:47–53CrossRefGoogle Scholar
  31. 31.
    Newman DL, Moffitt TE, Caspi A, Silva PA (1998) Comorbid mental disorders: implications for treatment and sample selection. J Abnorm Psychol 107:305–311PubMedCrossRefGoogle Scholar
  32. 32.
    Oiesvold T, Nivison M, Hansen V, Skre I, Ostensen L, Sørgaard KW (2013) Diagnosing comorbidity in psychiatric hospital: challenging the validity of administrative registers. BMC Psychiatry 13:13. doi: 10.1186/1471-244X-13-13 PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Øiesvold T, Nivison M, Hansen V, Sørgaard KW, Østensen L, Skre I (2012) Classification of bipolar disorder in psychiatric hospital. a prospective cohort study. BMC Psychiatry 12:13–14. doi: 10.1186/1471-244X-12-13 PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Jakobsen KD, Frederiksen JN, Hansen T, Jansson LB, Parnas J, Werge T (2005) Reliability of clinical ICD-10 schizophrenia diagnoses. Nord J Psychiatry 59:209–212PubMedCrossRefGoogle Scholar
  35. 35.
    Dalman C, Broms J, Cullberg J, Allebeck P (2002) Young cases of schizophrenia identified in a national inpatient register—are the diagnoses valid? Soc Psychiatry Psychiatr Epidemiol 37:527–531PubMedCrossRefGoogle Scholar
  36. 36.
    Ekholm B, Ekholm A, Adolfsson R, Vares M, Osby U, Sedvall GC, Jönsson EG (2005) Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nord J Psychiatry 59:457–464PubMedCrossRefGoogle Scholar
  37. 37.
    Pihlajamaa J, Suvisaari J, Henriksson M, Heilä H, Karjalainen E, Koskela J, Cannon M, Lönnqvist J (2008) The validity of schizophrenia diagnosis in the Finnish Hospital Discharge Register: findings from a 10-year birth cohort sample. Nord J Psychiatry 62:198–203PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Ragnar Nesvåg
    • 1
  • Gun Peggy Knudsen
    • 1
  • Inger Johanne Bakken
    • 1
  • Anne Høye
    • 1
    • 2
  • Eivind Ystrom
    • 1
  • Pål Surén
    • 1
  • Anne Reneflot
    • 1
  • Camilla Stoltenberg
    • 1
    • 3
  • Ted Reichborn-Kjennerud
    • 1
    • 4
  1. 1.Norwegian Institute of Public HealthOsloNorway
  2. 2.Centre for Clinical Documentation and EvaluationRegional Health Authority of North NorwayTromsøNorway
  3. 3.Department of Global Public Health and Primary CareUniversity of BergenBergenNorway
  4. 4.Institute of Clinical MedicineUniversity of OsloOsloNorway

Personalised recommendations